Craig Eckfeldt, MD, PhD, discusses the current treatment paradigm in MDS and the unmet needs in different subsets of patients.
Craig Eckfeldt, MD, PhD
Advertisement
Articles by Craig Eckfeldt, MD, PhD
Craig Eckfeldt, MD, PhD, discusses how improved minimal residual disease testing methods have impacted the acute myeloid leukemia treatment paradigm.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
2
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
3
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
4
FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer
5